Synthetic Lethality in Cancer Therapeutics - OICR Mondays

Challenges associated with synthetic lethality in cancer therapeuticsПодробнее

Therapeutic targeting of metabolic synthetic lethality in cancer researchПодробнее

OICR Mondays - Genomic Interpretation of VariantsПодробнее

Opportunities and Challenges of Exploiting Synthetic Lethality in CancerПодробнее

CRISPR screens to identify novel DNA repair defects synthetic lethal therapiesПодробнее

Dr. Jeffrey Weitzel on Synthetic Lethality in BRCA-Associated CancerПодробнее

Drug Combinations for Synthetic Lethal Interactions | Protocol PreviewПодробнее

What is synthetic lethality?Подробнее

David Uehling - OICR's Drug Discovery ProgramПодробнее

What is synthetic lethality?Подробнее

Exploiting Synthetic Lethality To Improve Cancer TherapyПодробнее

Biomarker assays: From development to clinical adoptionПодробнее

OICR Mondays: 'Immuno-oncology — moving beyond the asymptote'Подробнее

Discovery of Synthetic Lethal Paralog Pairs in the Human Genome | Phoebe ParrishПодробнее

💊 Synthetic Lethality: Inhibition of PARPs in BRCA1 and BRCA2 gene mutation Cancers 🛑Подробнее

Targeting Ovarian CancerПодробнее

Philip Hieter: Chromosome Instability and Synthetic Lethality in Yeast and CancerПодробнее

Alex Fortuna - Interpretation of Clinical Cancer GenomesПодробнее